Key Takeaways Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the ...

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

This analysis is based on information available up to January 17, 2025, and market conditions may have changed since then. Gain an edge in your investment decisions with InvestingPro’s in-depth ...

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...

Preliminary InformationThe unaudited financial information presented in this press release is preliminary and may change as a result of, among other factors, Lilly's financial closing procedures ...

The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...

AbbVie continues to evaluate information with respect to the ... Berenberg decreased the firm’s price target on Eli Lilly to $970 from $1,050 and maintained a Buy rating on the shares.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to: Verify your identity, personalize the content you receive, or create ...

Inc shares on Thursday witnessed a significant surge, closing up 7% in contrast to the relatively flat performance of the S&P 500. Analysts at JP Morgan on Friday reiterated an Overweight (OW) rating ...

DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...